Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib

Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment.

32

Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J